ES3031295T3 - Composition comprising roginolisib and dosage regime for treating cancer or an inflammatory or autoimmune disease - Google Patents
Composition comprising roginolisib and dosage regime for treating cancer or an inflammatory or autoimmune diseaseInfo
- Publication number
- ES3031295T3 ES3031295T3 ES22719266T ES22719266T ES3031295T3 ES 3031295 T3 ES3031295 T3 ES 3031295T3 ES 22719266 T ES22719266 T ES 22719266T ES 22719266 T ES22719266 T ES 22719266T ES 3031295 T3 ES3031295 T3 ES 3031295T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- cancer
- salt
- treatment
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2104416.9A GB202104416D0 (en) | 2021-03-29 | 2021-03-29 | Treatment reginmens |
| GBGB2117511.2A GB202117511D0 (en) | 2021-12-03 | 2021-12-03 | Treatment regimens |
| PCT/EP2022/058283 WO2022207646A1 (en) | 2021-03-29 | 2022-03-29 | A pi3k-delta inhibitor for use in treatment regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3031295T3 true ES3031295T3 (en) | 2025-07-07 |
Family
ID=81388915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22719266T Active ES3031295T3 (en) | 2021-03-29 | 2022-03-29 | Composition comprising roginolisib and dosage regime for treating cancer or an inflammatory or autoimmune disease |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12605389B2 (https=) |
| EP (1) | EP4313058B1 (https=) |
| JP (1) | JP7839803B2 (https=) |
| AU (1) | AU2022251843B2 (https=) |
| CA (1) | CA3212731A1 (https=) |
| DK (1) | DK4313058T3 (https=) |
| ES (1) | ES3031295T3 (https=) |
| FI (1) | FI4313058T3 (https=) |
| HR (1) | HRP20250516T1 (https=) |
| HU (1) | HUE071610T2 (https=) |
| LT (1) | LT4313058T (https=) |
| MX (1) | MX2023011442A (https=) |
| PL (1) | PL4313058T3 (https=) |
| PT (1) | PT4313058T (https=) |
| RS (1) | RS66754B1 (https=) |
| SI (1) | SI4313058T1 (https=) |
| WO (1) | WO2022207646A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026510567A (ja) * | 2023-03-03 | 2026-04-08 | アイオンクチュラ・ソシエテ・アノニム | 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ |
| AU2024231699A1 (en) * | 2023-03-03 | 2025-09-11 | Ionctura Sa | Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201290305A1 (ru) | 2009-11-13 | 2012-12-28 | Мерк Сероно С.А. | Производные трициклического пиразоламина |
| WO2014121901A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Polymorphic forms |
| US9986723B2 (en) | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
-
2022
- 2022-03-29 WO PCT/EP2022/058283 patent/WO2022207646A1/en not_active Ceased
- 2022-03-29 CA CA3212731A patent/CA3212731A1/en active Pending
- 2022-03-29 AU AU2022251843A patent/AU2022251843B2/en active Active
- 2022-03-29 MX MX2023011442A patent/MX2023011442A/es unknown
- 2022-03-29 HR HRP20250516TT patent/HRP20250516T1/hr unknown
- 2022-03-29 PT PT227192663T patent/PT4313058T/pt unknown
- 2022-03-29 EP EP22719266.3A patent/EP4313058B1/en active Active
- 2022-03-29 DK DK22719266.3T patent/DK4313058T3/da active
- 2022-03-29 HU HUE22719266A patent/HUE071610T2/hu unknown
- 2022-03-29 SI SI202230137T patent/SI4313058T1/sl unknown
- 2022-03-29 FI FIEP22719266.3T patent/FI4313058T3/fi active
- 2022-03-29 PL PL22719266.3T patent/PL4313058T3/pl unknown
- 2022-03-29 LT LTEPPCT/EP2022/058283T patent/LT4313058T/lt unknown
- 2022-03-29 ES ES22719266T patent/ES3031295T3/es active Active
- 2022-03-29 JP JP2023560623A patent/JP7839803B2/ja active Active
- 2022-03-29 US US18/271,196 patent/US12605389B2/en active Active
- 2022-03-29 RS RS20250390A patent/RS66754B1/sr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT4313058T (pt) | 2025-06-02 |
| AU2022251843A1 (en) | 2023-10-05 |
| LT4313058T (lt) | 2025-05-26 |
| US20240058351A1 (en) | 2024-02-22 |
| RS66754B1 (sr) | 2025-05-30 |
| WO2022207646A1 (en) | 2022-10-06 |
| JP2024518685A (ja) | 2024-05-02 |
| US12605389B2 (en) | 2026-04-21 |
| PL4313058T3 (pl) | 2025-06-23 |
| AU2022251843B2 (en) | 2026-04-09 |
| HUE071610T2 (hu) | 2025-09-28 |
| EP4313058A1 (en) | 2024-02-07 |
| CA3212731A1 (en) | 2022-10-06 |
| SI4313058T1 (sl) | 2025-07-31 |
| EP4313058B1 (en) | 2025-03-05 |
| FI4313058T3 (fi) | 2025-04-30 |
| MX2023011442A (es) | 2023-10-18 |
| JP7839803B2 (ja) | 2026-04-02 |
| HRP20250516T1 (hr) | 2025-06-20 |
| DK4313058T3 (da) | 2025-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cocco et al. | Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models | |
| JP6280546B2 (ja) | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 | |
| TWI732353B (zh) | 藥物組成物及其用途 | |
| JP2019135268A (ja) | 準最適に投与された化学化合物の治療的有効性 | |
| US9364476B2 (en) | Methods of treating a Bruton's Tyrosine Kinase disease or disorder | |
| JP2012508775A (ja) | 血液学的な悪性疾患のための療法 | |
| ES2741399T3 (es) | Apilimod para el uso en el tratamiento de cáncer renal | |
| KR20180126497A (ko) | 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법 | |
| EA020022B1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа | |
| CN112472699A (zh) | 改善比生群及衍生物的治疗益处的组合方法 | |
| ES3031295T3 (en) | Composition comprising roginolisib and dosage regime for treating cancer or an inflammatory or autoimmune disease | |
| MX2013010439A (es) | Tratamientos combinados para neoplasias hematologicas. | |
| CN110636844A (zh) | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 | |
| JP2015536986A (ja) | 併用療法 | |
| CN105579044A (zh) | 双脱水半乳糖醇及其类似物与衍生物用于治疗复发性恶性神经胶瘤或进行性继发脑瘤的用途 | |
| KR20160126984A (ko) | 아필리모드 조성물 및 이를 사용하기 위한 방법 | |
| TW202033191A (zh) | 新穎藥物組成物及其用途 | |
| TW202021591A (zh) | B細胞惡性腫瘤之治療 | |
| TW202021593A (zh) | 復發性濾泡淋巴瘤之治療 | |
| CA2742743A1 (en) | Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitor | |
| US20070004767A1 (en) | Methods for treating neurofibromatosis 1 | |
| CN117042778A (zh) | 用于治疗方案的PI3K-δ抑制剂 | |
| ES3062815T3 (en) | Compositions for treating aging-associated impairments using ccr3-inhibitors |